Cumberland Pharma Hits $77.8M Q3 Net on $100M Apotex Deal

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) reported net income of $77.8 million for the third quarter of 2026, the company announced on Nov. 10, 2026, its first full quarter after closing a $100 million Strategic Transaction with Apotex Health on July 1, 2026. The Nashville-based biopharmaceutical company said it ended the period with $80.6 million in cash and cash equivalents, total assets of roughly $114 million, and $73 million in shareholders' equity, and confirmed plans to file a New Drug Application with the FDA for ifetroban in Duchenne muscular dystrophy cardiomyopathy.

Context — why the Apotex close resets the CPIX story

The third quarter marks the first reporting period in which Cumberland's commercial brands and organization sit inside Apotex's U.S. branded business, leaving Cumberland as a development-stage company focused on its clinical pipeline. That structural shift explains why the income statement now shows transition services revenue of $1.95 million against $206,356 of net revenue, with the legacy product economics moved into discontinued operations.

The prior-year comparable the report supplies is stark: Cumberland lost $1.9 million in Q3 2025, versus $77.8 million of net income in Q3 2026, a swing driven almost entirely by an $81.1 million gain on disposal of discontinued operations. Continuing operations remained loss-making at $1.1 million for the quarter, narrower than the $2.7 million loss a year earlier.

The catalyst chain runs from the July 1 close to the fall pre-NDA meeting with the FDA, which the company said produced agreement on a rolling review. That pathway lets Cumberland submit finished sections of the application before the full filing is assembled, compressing the timeline between data lock and regulatory submission.

Cumberland's balance sheet also changed shape. Cash and cash equivalents rose to $80.6 million from $11.4 million at Dec. 31, 2025, while a $5.2 million revolving line of credit was fully repaid and a $22.5 million cash dividend was paid during the nine-month period. The company is now funding research and development from its own cash rather than from commercial brand cash flow.

Data — what the numbers show

The quarter's headline figure is the $81.1 million gain on disposal of discontinued operations, offset by $467,657 of income tax expense on that disposal, producing $78.9 million of net income from discontinued operations. Continuing operations contributed a $1.1 million net loss, leaving consolidated net income at $77.8 million.

Metric	Q3 2026	Q3 2025
Total revenue	$2.16M	$0.17M
Research and development	$0.84M	$0.65M
Operating loss	$1.94M	$2.86M
Net income (loss)	$77.8M	-$1.9M
Diluted EPS	$5.07	-$0.13

Diluted earnings per share reached $5.07, of which $5.14 came from discontinued operations and negative $0.07 from continuing operations. Basic EPS was $5.19. Weighted-average diluted shares were 15.34 million.

On the balance sheet, liabilities totaled $41.6 million against $113.8 million in assets. Accounts receivable from the transition services arrangement stood at $10.4 million, with a further $10.6 million receivable from Apotex and a $6.9 million payable to Apotex.

For the nine months ended Sept. 30, 2026, net cash used in operating activities from continuing operations was $1.13 million, versus $2.52 million a year earlier, while discontinued operations delivered $99.98 million of investing cash inflow.

Analysis — what it means for healthcare and rare-disease names

The re-rating case for CPIX now rests on ifetroban rather than on commercial brands. The Phase 2 FIGHT DMD trial reported a statistically significant 5.4 percentage point improvement in left ventricular ejection fraction (p=0.002) in the high-dose group versus a combined control of placebo patients and propensity score-matched natural history patients, with the company also citing reduced markers of cardiac damage.

The company said the safety database spans more than 1,400 subjects across roughly 30 clinical studies, with no treatment-related serious adverse events through up to 36 months of treatment. Ifetroban holds Orphan Drug, Rare Pediatric Disease and Fast Track designations, and the FDA has conditionally accepted DYSCORBAN as the proprietary name.

The counter-argument is execution risk. The Phase 2a ASSIST-SSc trial in systemic sclerosis was generally well tolerated but produced no disclosed efficacy endpoint, and Cumberland said it will submit the clinical study report to the FDA while completing biomarker and cardiac imaging work before deciding on further development in that indication. A negative or ambiguous read there would not block the DMD filing but would narrow the pipeline's breadth.

Positioning is likely to hinge on the rolling NDA rather than the quarter's earnings, which are largely a one-time divestiture effect. Rare-disease specialists and event-driven funds are the natural holders into a submission, while generalist healthcare investors may treat the $5.07 diluted EPS as non-recurring.

Outlook — what to watch next

The primary catalyst is the ifetroban NDA submission for DMD cardiomyopathy, which the company said will be filed on a rolling basis following the fall pre-NDA meeting. Investors should watch for disclosure of which modules are submitted first, since that signals how close the application is to completion.

Second, Cumberland said it will send the ASSIST-SSc clinical study report to the FDA and complete correlative biomarker studies plus cardiac imaging from patients continuing in the open-label extension. Those results will determine whether ifetroban advances further in systemic sclerosis.

Third, the company continues Phase 2 work in idiopathic pulmonary fibrosis and cancer metastasis, though no timelines were given. No specific price levels were disclosed, and the report provides no guidance figures for the fourth quarter, so the cash balance of $80.6 million is the clearest runway marker available.

Frequently Asked Questions

What does Cumberland Pharmaceuticals' Q3 2026 net income actually reflect?

The $77.8 million net income is dominated by an $81.1 million accounting gain on the disposal of discontinued operations tied to the Apotex transaction, not by operating profit. Continuing operations lost $1.1 million in the quarter. Investors should treat the headline number as a one-time divestiture effect rather than a run-rate earnings figure for the newly development-focused company.

What happens next for the ifetroban DMD filing?

Cumberland said it will submit a rolling New Drug Application to the FDA for ifetroban in DMD cardiomyopathy, allowing completed sections to be reviewed before the full application is filed. The submission will draw on Phase 2 FIGHT DMD data, the open-label extension, preclinical data published in the Journal of the American Heart Association, manufacturing information and a safety database covering more than 1,400 subjects.

Why did Cumberland's revenue fall so sharply versus its commercial-brand era?

Revenue now reflects a development-stage company. Q3 2026 total revenue was $2.16 million, mostly $1.95 million of transition services revenue, because the commercial brands moved to Apotex on July 1, 2026, and their economics are reported in discontinued operations. Net revenue of $206,356 was a residual item. The comparison is structural, not a demand signal.

Bottom Line

Cumberland's quarter was a balance-sheet reset, and the ifetroban DMD filing is now the only catalyst that matters for CPIX.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.